贝那普利联合羟苯磺酸钙辅助胰岛素治疗老年早期糖尿病肾病的临床观察

发布时间：2018-02-17 03:25

本文关键词： 贝那普利羟苯磺酸钙胰岛素糖尿病肾病疗效安全性　出处：《中国药房》2017年03期 　论文类型：期刊论文

【摘要】：目的:观察贝那普利联合羟苯磺酸钙辅助胰岛素治疗老年早期糖尿病肾病的疗效和安全性。方法:200例老年早期糖尿病肾病患者随机分为对照组(100例)和观察组(100例)。两组患者均在睡前经胰岛素泵持续皮下注射重组人胰岛素注射液0.4~0.6单位/(kg·d),泵入量为每日总量的50%,其余剂量于每日三餐前平均分配,保证空腹血糖4.4~6.1 mmol/L和餐后2 h血糖4.4~8.0 mmol/L。在此基础上,对照组患者给予盐酸贝那普利片10 mg,口服,每日1次;观察组患者在对照组治疗的基础上给予羟苯磺酸钙胶囊0.5 g,口服,每日3次。两组均连用8周。观察两组患者的临床疗效,治疗前后的肾功能、胱抑素C(Cys-C)、超敏C反应蛋白(hs-CRP)、生活质量核心量表(QLQ-C30)评分及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P0.05)。治疗后,两组患者肾功能、Cys-C、hs-CRP水平均显著优于同组治疗前,且观察组显著优于对照组;两组患者QOL-C30评分显著高于同组治疗前,且观察组显著高于对照组,差异均有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:贝那普利联合羟苯磺酸钙辅助胰岛素治疗老年早期糖尿病肾病的疗效显著,可有效改善临床症状,促进肾功能恢复,提高生活质量,且不会增加不良反应的发生。
[Abstract]:Objective: to observe the efficacy and safety of benazepril combined with calcium dobesilate in the treatment of early diabetic nephropathy in the elderly. Methods: 200 cases of senile early diabetic nephropathy were randomly divided into two groups: control group (n = 100) and observation group (n = 100). The patients in both groups were continuously subcutaneously injected with recombinant human insulin injection (0.4 ~ 0.6 unit / kg 路d ~ (-1)) by insulin pump before bedtime. The pump volume was 50% of the total daily dose, and the remaining doses were equally distributed before three meals daily. On this basis, the patients in the control group were given benazepril hydrochloride 10 mg orally, once a day, and the patients in the observation group were given calcium dobesilate capsule 0.5 g orally on the basis of the treatment in the control group. Three times a day. The two groups were treated continuously for 8 weeks. The clinical efficacy and renal function before and after treatment were observed. Results: the total effective rate of the patients in the observation group was significantly higher than that in the control group, and the difference was statistically significant after treatment. The levels of Cys-Cn hs-CRP in the two groups were significantly better than those in the control group, and the QOL-C30 score of the two groups was significantly higher than that of the control group, and the QOL-C30 score of the observation group was significantly higher than that of the control group. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: benazepril combined with calcium dobesilate is effective in the treatment of early diabetic nephropathy in the elderly. It can effectively improve the clinical symptoms, promote the recovery of renal function, improve the quality of life, and does not increase the occurrence of adverse reactions.
【作者单位】：西南医科大学附属医院内分泌科;
【分类号】：R587.2;R692.9

【相似文献】